若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

EasySep™人CD271正选试剂盒 II

免疫磁珠正选细胞分选试剂盒

产品号 #(选择产品)

产品号 #17849_C

免疫磁珠正选细胞分选试剂盒

产品优势

  • 快捷、操作简单
  • 无需分离柱

产品组分包括

  • EasySep™ 人CD271正选试剂盒II(产品号 #17849)
    • EasySep™ 人CD271正选抗体混合物 II,1 mL
    • EasySep™ Dextran RapidSpheres™ 50100 磁珠,1 mL
    • EasySep™ 人FcR阻断剂,1 mL
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
专为您的实验方案打造的产品

总览

EasySep™人CD271正选试剂盒 II 专为从人新鲜骨髓中通过正选分离CD271+细胞而设计。目的细胞被识别CD271的抗体四聚体复合物和葡聚糖包被的磁珠标记,试剂盒中还含有人Fc受体的结合抗体,可最大程度减少非特异性结合。通过EasySep™磁极进行无柱分选,标记的细胞保留在分离管中,未被标记的细胞倒出即可。CD271抗原表达于多种细胞类型,包括间充质干细胞和祖细胞(MSCs)。

该产品可替代EasySep™人CD271正选试剂盒 (产品号 #18659) 以进行更快的细胞分选。

该产品可替代EasySep™人CD271正选试剂盒 (产品号 #18659) 以进行更快的细胞分选。

该产品可替代EasySep™人CD271正选试剂盒 (产品号 #18659) 以进行更快的细胞分选。

该产品可替代EasySep™人CD271正选试剂盒 (产品号 #18659) 以进行更快的细胞分选。

磁体兼容性
EasySep™ Magnet (Catalog #18000)
 
亚型
细胞分选试剂盒
 
细胞类型
间充质干/祖细胞
 
种属

 
样本来源
Bone Marrow
 
筛选方法
Positive
 
应用
细胞分选
 
品牌
EasySep
 
研究领域
干细胞生物学
 

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明,或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
17849
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17849
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17849
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
17849
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计,适用于工作流程中的高亮阶段。探索这些工作流程,了解更多我们为各研究领域提供的其他配套产品。

相关材料与文献

技术资料 (6)

文献 (1)

Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization. N. Camviel et al. Journal for immunotherapy of cancer 2022 nov

Abstract

BACKGROUND Chimeric antigen receptor (CAR) T cell therapy targeting B cell maturation antigen (BCMA) on multiple myeloma (MM) produces fast but not long-lasting responses. Reasons for treatment failure are poorly understood. CARs simultaneously targeting two antigens may represent an alternative. Here, we (1) designed and characterized novel A proliferation inducing ligand (APRIL) based dual-antigen targeting CARs, and (2) investigated mechanisms of resistance to CAR T cells with three different BCMA-binding moieties (APRIL, single-chain-variable-fragment, heavy-chain-only). METHODS Three new APRIL-CARs were designed and characterized. Human APRIL-CAR T cells were evaluated for their cytotoxic function in vitro and in vivo, for their polyfunctionality, immune synapse formation, memory, exhaustion phenotype and tonic signaling activity. To investigate resistance mechanisms, we analyzed BCMA levels and cellular localization and quantified CAR T cell-target cell interactions by live microscopy. Impact on pathway activation and tumor cell proliferation was assessed in vitro and in vivo. RESULTS APRIL-CAR T cells in a trimeric ligand binding conformation conferred fast but not sustained antitumor responses in vivo in mouse xenograft models. In vitro trimer-BB$\zeta$ CAR T cells were more polyfunctional and formed stronger immune synapses than monomer-BB$\zeta$ CAR T cells. After CAR T cell-myeloma cell contact, BCMA was rapidly downmodulated on target cells with all evaluated binding moieties. CAR T cells acquired BCMA by trogocytosis, and BCMA on MM cells was rapidly internalized. Since BCMA can be re-expressed during progression and persisting CAR T cells may not protect patients from relapse, we investigated whether non-functional CAR T cells play a role in tumor progression. While CAR T cell-MM cell interactions activated BCMA pathway, we did not find enhanced tumor growth in vitro or in vivo. CONCLUSION Antitumor responses with APRIL-CAR T cells were fast but not sustained. Rapid BCMA downmodulation occurred independently of whether an APRIL or antibody-based binding moiety was used. BCMA internalization mostly contributed to this effect, but trogocytosis by CAR T cells was also observed. Our study sheds light on the mechanisms underlying CAR T cell failure in MM when targeting BCMA and can inform the development of improved treatment strategies.

更多信息

更多信息
种属 Human
Magnet Compatibility EasySep™ Magnet (Catalog #18000)
样本来源 Bone Marrow
Selection Method Positive
质量保证:

产品仅供研究使用,不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息,请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.